文献速递肝病消化道出血

降低门脉压力改善肝硬化患者结局:伴或不伴腹水的荟萃分析

Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-06-05

该荟萃分析纳入15项研究共1113例肝硬化患者,比较HVPG应答者与非应答者在伴或不伴腹水时的临床结局。结果显示,无论有无腹水,应答者的事件(如静脉曲张出血、难治性腹水等)及死亡/肝移植风险均显著低于非应答者。

要点

  • 无腹水患者中,应答者事件风险OR 0.35,死亡/肝移植OR 0.50。
  • 有腹水患者中,应答者事件风险OR 0.27,死亡/肝移植OR 0.47。
  • HVPG应答定义多为较基线下降>20%或降至<12 mm Hg。

核心结论

  • 伴或不伴腹水的肝硬化患者,对非选择性β受体阻滞剂治疗产生HVPG应答者,其事件、死亡或肝移植风险降低。

研究设计与样本

  • 荟萃分析,纳入15项关于静脉曲张出血一级或二级预防的研究,共1113例肝硬化患者。

主要发现

  • 无腹水患者661例中应答者329例(50%),应答者事件(腹水、静脉曲张出血或肝性脑病)OR 0.35(95%CI 0.22-0.56),死亡或肝移植OR 0.50(95%CI 0.32-0.78)。
  • 有腹水患者452例中应答者188例(42%),应答者事件(静脉曲张出血、难治性腹水、自发性细菌性腹膜炎或肝肾综合征)OR 0.27(95%CI 0.16-0.43),死亡或肝移植OR 0.47(95%CI 0.29-0.75)。
  • 研究间未见异质性。

关键数值与推荐

  • 993例(89%)患者HVPG应答定义为较基线下降>20%(其中11%患者定义为>10%)或降至<12 mm Hg。
  • 968例(87%)患者接受非选择性β受体阻滞剂治疗。

临床怎么用

  • 原文未述及临床实践建议。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: In unselected patients with cirrhosis, those with reductions in hepatic venous pressure gradient (HVPG) to below a defined threshold (responders) have a reduced risk of variceal hemorrhage (VH) and death. We performed a meta-analysis to compare this effect in patients with vs without ascites. METHODS: We collected data from 15 studies of primary or secondary prophylaxis of VH that reported data on VH and death in responders vs nonresponders. We included studies in which data on ascites at baseline and on other relevant outcomes during follow-up evaluation were available. We performed separate meta-analyses for patients with vs without ascites. RESULTS: Of the 1113 patients included in the studies, 968 patients (87%) had been treated with nonselective β-blockers. In 993 patients (89%), HVPG response was defined as a decrease of more than 20% from baseline (>10% in 11% of patients) or to less than 12 mm Hg. In the 661 patients without ascites, responders (n = 329; 50%) had significantly lower odds of events (ascites, VH, or encephalopathy) than nonresponders (odds ratio [OR], 0.35; 95% CI, 0.22-0.56). Odds of death or liver transplantation were also significantly lower among responders than nonresponders (OR, 0.50, 95% CI, 0.32-0.78). In the 452 patients with ascites, responders (n = 188; 42%) had significantly lower odds of events (VH, refractory ascites, spontaneous bacterial peritonitis, or hepatorenal syndrome) than nonresponders (OR, 0.27; 95% CI, 0.16-0.43). Overall, odds of death or liver transplantation were lower among responders (OR, 0.47; 95% CI, 0.29-0.75). No heterogeneity was observed among studies. CONCLUSIONS: In a meta-analysis of clinical trials, we found that patients with cirrhosis with and without ascites who respond to treatment with nonselective β-blockers (based on reductions in HVPG) have a reduced risk of events, death, or liver transplantation.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Turco L, Villanueva C, La Mura V, et al. Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. Clin Gastroenterol Hepatol. 2019. PMID: 31176013. doi:10.1016/j.cgh.2019.05.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。